ocrelizumabOCRPwRMSPw) relapsing and primary progressive multiple sclerosis
…( NCT03972306) and II (NCT05232825) show that subcutaneous (SC) ocrelizumab (OCR) 920 mg has a similar benefit-risk profile to intravenous …
1articles mentioning drugs
2drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: OCR ×
OCR
This drug is selected. Its supporting articles are shown below.